| Dina Marcela Duran, | |
|
18900 Wentworth Dr, Hialeah, FL 33015-2922 | |
| (305) 498-9595 | |
| Not Available |
| Full Name | Dina Marcela Duran |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 18900 Wentworth Dr, Hialeah, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013624873 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 11022431 (Florida) | Primary |
| Entity Name | Physicians Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568429363 PECOS PAC ID: 9739146663 Enrollment ID: O20041213000719 |
News Archive
HCP announced that it closed the acquisition of 334 post-acute, skilled nursing and assisted living facilities of HCR ManorCare for a total consideration of $6.1 billion in cash. In connection with the closing, HCP entered into a long-term triple-net master lease under which HCR ManorCare will continue to operate the facilities.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
Health care reform has caused some unrest in the health care industry but has also led to strong deal-making and mergers.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Diagnostics company SphingoTec GmbH ("sphingotec") and 4TEEN4 Pharmaceuticals GmbH ("4TEEN4") announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dina Marcela Duran, 18900 Wentworth Dr, Hialeah, FL 33015-2922 Ph: (305) 498-9595 | Dina Marcela Duran, 18900 Wentworth Dr, Hialeah, FL 33015-2922 Ph: (305) 498-9595 |
News Archive
HCP announced that it closed the acquisition of 334 post-acute, skilled nursing and assisted living facilities of HCR ManorCare for a total consideration of $6.1 billion in cash. In connection with the closing, HCP entered into a long-term triple-net master lease under which HCR ManorCare will continue to operate the facilities.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
Health care reform has caused some unrest in the health care industry but has also led to strong deal-making and mergers.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Diagnostics company SphingoTec GmbH ("sphingotec") and 4TEEN4 Pharmaceuticals GmbH ("4TEEN4") announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.
› Verified 3 days ago
Ms. Albertina Onelia De La Osa, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 18530 Nw 81st Ct, Hialeah, FL 33015 Phone: 305-582-6837 | |
Hendrick Vega Medina, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 18300 Nw 62nd Ave Ste 100, Hialeah, FL 33015 Phone: 305-749-6203 Fax: 786-520-3173 | |
Emilio Guerrero, NURSE PRACTITIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4450 W 16th Ave Apt 524, Hialeah, FL 33012 Phone: 786-269-4060 | |
Iraisy Mendez, PMHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1055 W 77th St Apt 311, Hialeah, FL 33014 Phone: 786-332-9540 | |
Yarlie Vincent, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2001 W 68th St, Hialeah, FL 33016 Phone: 786-520-1799 | |
Cindy Julieth Jaimes Marroquin, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2001 W 68th St, Hialeah, FL 33016 Phone: 305-823-5000 |